**Blood- Blood Products Hemophilia Factors**

| Criteria 1 | Non-Preferred Agents- Altuviiio, Jivi, Nuwiq, Obizur, Rebinyn, Sevenfact, Vonvendi                                                                                                                                                                                                                                  |
| ---------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Criteria 2 | Preferred Agents (all require PA)- Advate, Adynovate, Afstyla, Alphanate, Alphanine SD, Alprolix, Benefix, Corifact, Eloctate, Esperoct, Feiba, Hemlibra, Hemofil M, Humate-P, Idelvion, Ixinity, Koate, Kogenate FS, Kovaltry, Mononine, Novoeight, Novoseven RT, Profilnine, Recombinate, Rixubis, Wilate, Xyntha |

  

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong></th>
<th>Blood Formation, Coagulation, and Thrombosis Agents: Hemophilia Factor</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong></td>
<td>Non-Preferred Products</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong></td>
<td>HICL</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products</strong></p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name</td>
<td>Corresponding Code (s)</td>
<td>Type of Code (GCNSeqNo, HICL, NDC)</td>
</tr>
<tr class="even">
<td></td>
<td>ALTUVIIIO</td>
<td>084449</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ALTUVIIIO</td>
<td>084450</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ALTUVIIIO</td>
<td>084452</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ALTUVIIIO</td>
<td>084453</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ALTUVIIIO</td>
<td>084454</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ALTUVIIIO</td>
<td>084455</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>JIVI</td>
<td>078823</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>JIVI</td>
<td>078824</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>JIVI</td>
<td>078825</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>JIVI</td>
<td>078826</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NUWIQ</td>
<td>073599</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NUWIQ</td>
<td>073600</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NUWIQ</td>
<td>073601</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NUWIQ</td>
<td>073603</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NUWIQ</td>
<td>077688</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NUWIQ</td>
<td>077689</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NUWIQ</td>
<td>077690</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NUWIQ</td>
<td>083164</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>OBIZUR</td>
<td>073007</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>REBINYN</td>
<td>077458</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>REBINYN</td>
<td>077459</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>REBINYN</td>
<td>077460</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SEVENFACT</td>
<td>080904</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SEVENFACT</td>
<td>080905</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>VONVENDI</td>
<td>075253</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>VONVENDI</td>
<td>075254</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number</strong> </th>
<th><strong>Question ID</strong> </th>
<th><strong>Default Next Question ID</strong> </th>
<th><strong>Question Type</strong> </th>
<th><strong>Question Text</strong> </th>
<th><strong>Choice Text</strong> </th>
<th><strong>Next Question ID</strong> </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0999</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient taken the drug in the previous 120 days?   </p>
<p>If yes, please submit documentation of recent use.</p></td>
<td>Y </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1000</td>
</tr>
<tr class="odd">
<td>2 </td>
<td>1000</td>
<td></td>
<td>Select  </td>
<td>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?    </td>
<td>New Start (initial authorization request)</td>
<td>1001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)</td>
<td>1234</td>
</tr>
<tr class="odd">
<td>3 </td>
<td>1001 </td>
<td> </td>
<td>Select and Free Text </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?   </td>
<td>Y  </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1002 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">14 days</span> with at least <span class="underline">one preferred</span> drug?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1003</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1003 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y </td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1236</td>
</tr>
<tr class="odd">
<td>6 </td>
<td>1004</td>
<td></td>
<td>Select </td>
<td>Is the requested drug an extended half-life factor?</td>
<td>Y </td>
<td>1005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1006</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1005</td>
<td></td>
<td>Select </td>
<td>For extended half-life factors, does the prescribing physician attest that the patient is not a suitable candidate for treatment with shorter-acting half-life product?</td>
<td>Y </td>
<td>1006</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1006</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s body weight?</td>
<td>Y  </td>
<td>1007 </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>9</td>
<td>1007</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1008</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>10</td>
<td>1008</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>11</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring? </p>
<p> </p></td>
<td>Y  </td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>12</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>13</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong></th>
<th>Blood Formation, Coagulation, and Thrombosis Agents: Hemophilia Factor</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong></td>
<td>Preferred Products</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong></td>
<td>HICL</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products</strong></p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td></td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name</td>
<td>Corresponding Code (s)</td>
<td>Type of Code (GCNSeqNo, HICL, NDC)</td>
</tr>
<tr class="even">
<td></td>
<td>ADVATE</td>
<td>062863</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ADVATE</td>
<td>063004</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ADVATE</td>
<td>063070</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ADVATE</td>
<td>063071</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ADVATE</td>
<td>063072</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ADVATE</td>
<td>063073</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ADVATE</td>
<td>069604</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ADYNOVATE</td>
<td>075197</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ADYNOVATE</td>
<td>075198</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ADYNOVATE</td>
<td>075199</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ADYNOVATE</td>
<td>075200</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ADYNOVATE</td>
<td>077111</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ADYNOVATE</td>
<td>077114</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ADYNOVATE</td>
<td>077369</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>AFSTYLA</td>
<td>076202</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>AFSTYLA</td>
<td>076204</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>AFSTYLA</td>
<td>076205</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>AFSTYLA</td>
<td>076206</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>AFSTYLA</td>
<td>076207</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>AFSTYLA</td>
<td>077164</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>AFSTYLA</td>
<td>077165</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ALPHANATE</td>
<td>061157</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ALPHANATE</td>
<td>061158</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ALPHANATE</td>
<td>051159</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ALPHANATE</td>
<td>061160</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ALPHANATE</td>
<td>072729</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ALPHANINE SD</td>
<td>045641</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ALPHANINE SD</td>
<td>045642</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ALPHANINE SD</td>
<td>065140</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ALPROLIX</td>
<td>072211</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ALPROLIX</td>
<td>072212</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ALPROLIX</td>
<td>072216</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ALPROLIX</td>
<td>072214</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ALPROLIX</td>
<td>075710</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ALPROLIX</td>
<td>076768</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>BENEFIX</td>
<td>071162</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>BENEFIX</td>
<td>071163</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>BENEFIX</td>
<td>071164</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>BENEFIX</td>
<td>071165</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>BENEFIX</td>
<td>071166</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>CORIFACT</td>
<td>067103</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ELOCTATE</td>
<td>072433</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ELOCTATE</td>
<td>072434</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ELOCTATE</td>
<td>072435</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ELOCTATE</td>
<td>072436</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ELOCTATE</td>
<td>072437</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ELOCTATE</td>
<td>072438</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ELOCTATE</td>
<td>072439</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ELOCTATE</td>
<td>077183</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ELOCTATE</td>
<td>077184</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ELOCTATE</td>
<td>077185</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ESPEROCT</td>
<td>080614</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ESPEROCT</td>
<td>080615</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ESPEROCT</td>
<td>080616</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ESPEROCT</td>
<td>080617</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ESPEROCT</td>
<td>080618</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FEIBA</td>
<td>060240</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>FEIBA</td>
<td>079795</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FEIBA</td>
<td>079796</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>HEMLIBRA</td>
<td>077934</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>HEMLIBRA</td>
<td>077935</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>HEMLIBRA</td>
<td>077936</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>HEMLIBRA</td>
<td>077937</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>HEMOFIL M</td>
<td>060598</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>HEMOFIL M</td>
<td>060599</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>HEMOFIL M</td>
<td>067605</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>HEMOFIL M</td>
<td>067606</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>HUMATE-P</td>
<td>060323</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>HUMATE-P</td>
<td>060324</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>HUMATE-P</td>
<td>060325</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>IDELVION</td>
<td>075661</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>IDELVION</td>
<td>075662</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>IDELVION</td>
<td>075663</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>IDELVION</td>
<td>075664</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>IDELVION</td>
<td>078521</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>IXINITY</td>
<td>074098</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>IXINITY</td>
<td>074100</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>IXINITY</td>
<td>074101</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>IXINITY</td>
<td>077223</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>IXINITY</td>
<td>077224</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>IXINITY</td>
<td>077225</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>KOATE</td>
<td>006353</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>KOATE</td>
<td>026889</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>KOATE</td>
<td>026890</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>KOGENATE FS</td>
<td>062863</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>KOGENATE FS</td>
<td>063004</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>KOGENATE FS</td>
<td>063071</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>KOGENATE FS</td>
<td>063072</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>KOGENATE FS</td>
<td>063703</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>KOVALTRY</td>
<td>062863</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>KOVALTRY</td>
<td>063004</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>KOVALTRY</td>
<td>063071</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>KOVALTRY</td>
<td>063072</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>KOVLATRY</td>
<td>063073</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>MONONINE</td>
<td>045642</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NOVOEIGHT</td>
<td>073068</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NOVOEIGHT</td>
<td>073069</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NOVOEIGHT</td>
<td>073070</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NOVOEIGHT</td>
<td>073071</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NOVOEIGHT</td>
<td>073072</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NOVOEIGHT</td>
<td>073073</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NOVOSEVEN RT</td>
<td>063985</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NOVOSEVEN RT</td>
<td>063986</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NOVOSEVEN RT</td>
<td>063987</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NOVOSEVEN RT</td>
<td>066677</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>PROFILNINE</td>
<td>006361</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>PROFILNINE</td>
<td>006363</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>PROFILNINE</td>
<td>027098</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>RECOMBINATE</td>
<td>018739</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>RECOMBINATE</td>
<td>018740</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>RECOMBINATE</td>
<td>018741</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>RECOMBINATE</td>
<td>060628</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>RECOMBINATE</td>
<td>060766</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>RIXUBIS</td>
<td>071162</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>RIXUBIS</td>
<td>071163</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>RIXUBIS</td>
<td>071164</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>RIXUBIS</td>
<td>071165</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>RIXUBIS</td>
<td>071166</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>WILATE</td>
<td>069253</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>WILATE</td>
<td>069254</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>XYNTHA</td>
<td>064164</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>XYNTHA</td>
<td>064165</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>XYNTHA</td>
<td>064166</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>XYNTHA</td>
<td>064167</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>XYNTHA</td>
<td>066952</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>XYNTHA</td>
<td>067808</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>XYNTHA</td>
<td>067809</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>XYNTHA</td>
<td>068428</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>XYNTHA</td>
<td>068429</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

 

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number</strong> </th>
<th><strong>Question ID</strong> </th>
<th><strong>Default Next Question ID</strong> </th>
<th><strong>Question Type</strong> </th>
<th><strong>Question Text</strong> </th>
<th><strong>Choice Text</strong> </th>
<th><strong>Next Question ID</strong> </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient taken the drug in the previous 120 days?   </p>
<p>If yes, please submit documentation of recent use.</p></td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1002</td>
</tr>
<tr class="odd">
<td>2</td>
<td>1002</td>
<td></td>
<td>Select  </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?    </p>
<p>    </p></td>
<td>New Start (initial authorization request)  </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)</td>
<td>1234</td>
</tr>
<tr class="odd">
<td>3</td>
<td>1003</td>
<td></td>
<td>Select and Free Text </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?   </td>
<td>Y  </td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1004</td>
<td></td>
<td>Select </td>
<td>Is the requested drug an extended half-life factor?</td>
<td>Y </td>
<td>1005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1006</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1005</td>
<td></td>
<td>Select </td>
<td>For extended half-life factors, does the prescribing physician attest that the patient is not a suitable candidate for treatment with shorter-acting half-life product?</td>
<td>Y </td>
<td>1006</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1006</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s body weight?</td>
<td>Y  </td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring? </td>
<td>Y  </td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>8</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |
